Non-Invasive Radiological Predictors Of Portal Hypertension And Variceal Bleeding In Chronic Liver Disease Patients: A Prospective Cohort Study At Hayatabad Medical Complex, Peshawar
DOI:
https://doi.org/10.36283/ziun-pjmd14-4/063Keywords:
Chronic liver disease, portal hypertension, variceal bleeding, non-invasive predictors, liver stiffness measurement, spleen stiffness, platelet count-to-spleen diameter ratio, transient elastography, prospective cohortAbstract
Background:
Portal hypertension and variceal bleeding are leading causes of morbidity and mortality in chronic liver disease (CLD). Invasive tools remain the gold standard for risk assessment, but resource and patient constraints demand validated, non-invasive alternatives, especially in low- and middle-income settings. To determine the diagnostic and prognostic accuracy of non-invasive radiological predictors for portal hypertension and first variceal bleeding in patients with CLD at Hayatabad Medical Complex, Peshawar.
Methods:
A prospective cohort of 371 adults with cirrhosis was followed for 12 months (May 2024–May 2025). All patients underwent standardized assessment with transient elastography (FibroScan®), contrast-enhanced ultrasound, and MRI. Baseline liver stiffness measurement (LSM), spleen stiffness measurement (SSM), splenic size, portal vein diameter, and platelet count-to-spleen diameter ratio (PSR) were evaluated. Multivariable Cox regression and AUROC analyses identified predictors of portal hypertension and first variceal bleed.
Results:
Portal hypertension was present in 222/371 (59.8%) at baseline. Over 12 months, 54 patients (14.6%) developed a first variceal bleed. LSM >20 kPa (HR 3.31, 95% CI 2.01–5.44), SSM >46 kPa (HR 2.89, 95% CI 1.67–4.99), portal vein diameter >13 mm (HR 2.61, 95% CI 1.51–4.51), splenomegaly (HR 2.45, 95% CI 1.19–4.97), and PSR <909 (HR 2.38, 95% CI 1.32–4.28) independently predicted variceal bleeding. The combined non-invasive model achieved an AUROC of 0.88 (95% CI 0.83–0.92). Subgroup and sensitivity analyses confirmed robustness across etiology, sex, and Child-Pugh class.
Conclusions:
A combination of liver and spleen stiffness and simple ultrasound indices offers high diagnostic and prognostic accuracy for portal hypertension and variceal bleeding in CLD. Adoption of these non-invasive tools could significantly improve risk stratification and reduce the need for routine endoscopy, particularly in resource-limited settings.
References
1. Bosch J, Abraldes JG, Berzigotti A, et al. Portal hypertension and variceal bleeding—unresolved issues. Liver Int. 2020;40(S1):36-42.
2. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2019;70(5):956-965.
3. de Franchis R. Expanding consensus in portal hypertension: Report of the Baveno VII Consensus Workshop. J Hepatol. 2022;76(5):959-974.
4. Zipprich A, Garcia-Tsao G. The HVPG: a still valid gold standard for portal hypertension? Hepatology. 2018;68(6):2310-2312.
5. Butt AS, Hamid S, Jafri W. Hepatology in Pakistan: challenges and future directions. Euroasian J Hepatogastroenterol. 2021;11(1):8-14.
6. Zaman J, Ghafoor F, Iqbal S, et al. Cost-effectiveness of noninvasive assessment for liver disease in Pakistan. J Pak Med Assoc. 2020;70(12):2232-2237.
7. Berzigotti A. Non-invasive assessment of portal hypertension using ultrasound and elastography. J Hepatol. 2022;77(2):455-466.
8. Colecchia A, Montrone L, Scaioli E, et al. Measurement of spleen stiffness to evaluate portal hypertension and the risk of varices in cirrhosis. Clin Gastroenterol Hepatol. 2019;17(12):2470-2477.
9. de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII criteria for avoiding unnecessary endoscopy. J Hepatol. 2022;76(5):959-974.
10. Qureshi MO, Khokhar N, Shafqat F, et al. Noninvasive predictors of esophageal varices in chronic liver disease: experience from Pakistan. J Coll Physicians Surg Pak. 2020;30(6):567-572.
11. Abbas Z, Shazi L, Jafri W. The epidemiology of hepatitis C in Pakistan: recent estimates. Gut Liver. 2021;15(6):883-889.
12. Afridi M, Khan H, Iqbal SP, et al. Burden of liver disease and the role of tertiary centers in Pakistan. J Ayub Med Coll Abbottabad. 2022;34(2):227-231.
13. Kim SU, Han KH, Ahn SH. Liver stiffness measurement predicts the risk of portal hypertension and varices. Gut Liver. 2022;16(1):1-11.
14. Wong GL, Chan HL, Choi PC, et al. Noninvasive predictors of varices and portal hypertension: validation in Asian populations. Hepatol Int. 2019;13(4):382-390.
15. Pons M, et al. Noninvasive tools for evaluation of portal hypertension. Hepatology. 2021;74(3):1395-1408.
16. Maurice JB, et al. Validation of the Baveno VII criteria in real-world patients. Liver Int. 2023;43(3):574-582.
17. Colecchia A, et al. Spleen stiffness predicts clinical events in cirrhosis. J Hepatol. 2022;76(4):876-885.
18. Stefanescu H, et al. Spleen stiffness measurement: ready for prime time? Liver Int. 2021;41(2):247-255.
19. Xu X, et al. Platelet count/spleen diameter ratio for the prediction of esophageal varices. World J Gastroenterol. 2020;26(5):541-553.
20. Sharma P, et al. Non-invasive prediction of large esophageal varices using clinical, laboratory and imaging parameters. J Gastroenterol Hepatol. 2019;34(5):855-862.
21. Stine JG, et al. Incidence and risk factors for variceal bleeding in cirrhosis: a meta-analysis. Am J Gastroenterol. 2020;115(7):998-1008.
22. Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: current best practice. J Hepatol. 2021;74(4):1044-1060.
23. Lee HA, et al. Performance of noninvasive markers in predicting variceal bleeding. Liver Int. 2022;42(5):1145-1155.
24. de Mattos AZ, et al. Prognostic value of noninvasive markers for varices. Hepatol Commun. 2021;5(7):1234-1241.
25. Sigrist RMS, et al. Ultrasound elastography: review of techniques and clinical applications. World J Gastroenterol. 2021;27(39):6657-6678.
26. Thiele M, et al. Noninvasive diagnosis of portal hypertension. J Hepatol. 2020;73(6):1363-1376.
27. Butt AS, et al. Challenges in cirrhosis care in low-resource settings. World J Hepatol. 2021;13(8):924-934.
28. La Mura V, et al. Prognostic role of noninvasive tests for portal hypertension. J Hepatol. 2021;74(6):1396-1407.
29. Qureshi MO, et al. Updating Pakistani guidelines for cirrhosis management. J Pak Med Assoc. 2023;73(4):784-792.
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of portal hypertension. J Hepatol. 2022;76(4):1104-1141.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
